PET Imaging of MMP Activation in AAA: Clinical Component
NCT07473102
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A first-in-human evaluation of [64Cu]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Abdominal Aortic Aneurysm
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Washington University School of Medicine
- Last updated on ClinicalTrials.gov
- March 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.